ClinicalTrials.gg
CompletedNCT07001475Updated Aug 10, 2026

A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

A Phase 1 interventional study of BI 3031185 and Placebo in Borderline Personality Disorder and Attention Deficit Hyperactivity Disorder, sponsored by Boehringer Ingelheim. Completed at 7 sites in Germany. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Borderline Personality Disorder with a site in Germany — 6 open to participants now, 7 under way, none of them phase 3. Borderline Personality Disorder · Germany.

Enrollment
18th of 28
78 · median 120
Started
2025
with 1 other
Phase 1
Only one
of the 37
Registered
35th of 37
by date
Lead sponsor
2 of 37
Boehringer Ingelheim

Among the 37 studies in Borderline Personality Disorder with a site in Germany, this one is the 18th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 1, and was the 35th registered.

Borderline Personality Disorder

278 studies on the registry are indexed under Borderline Personality Disorder; 69 are open to participants now.

Browse Borderline Personality Disorder studies →

Open to participants now

6 of the 37 studies in Borderline Personality Disorder with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 48 Borderline Personality Disorder studies recruiting now, 18 (38%) set no upper age limit and 29 (60%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Borderline Personality Disorder with a site in Germany, or all of them as a file.
02

Study summary

This study is open to adults with certain mental health conditions. The purpose of this study is to find out how a medicine called BI 3031185 is tolerated by people with certain mental health conditions.

Participants are put into 2 groups of equal size randomly, which means by chance. Group 1 takes a single dose of BI 3031185 and Group 2 takes placebo. After a 2-week break, Group 1 takes placebo and Group 2 takes a single dose of BI 3031185. Participants take BI 3031185 and placebo as tablets.

Participants are in the study for about 3 months. They visit the study site 6 times and have 3 phone or video call visits. For 2 of the visits, participants stay overnight at the study site for 2 nights. During all the visits, doctors check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Borderline Personality Disorder
  • Attention Deficit Hyperactivity Disorder
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, female, and non-binary participants, 18 to 45 years of age, both inclusively, at the time of consent
  • Meet current , fifth edition (DSM-5) criteria as primary diagnosis as assessed by the mini international neuropsychiatric interview (MINI) at screening for borderline personality disorder (BPD) OR attention-deficit/hyperactivity disorder (ADHD). With full implementation of version 5.0 of this clinical trial protocol (CTP), only participants with a primary diagnosis of ADHD as assessed by the MINI will be included in the trial.
  • Willingness to abstain from alcohol for 24 h, and all other drugs of abuse including cannabis for 72 h prior to Visits 2 and 3 (Day -1). Willingness to abstain from alcohol and cannabis for 72 h after medicinal product (IMP) administration, as well as from all other recreational drugs for the duration of the trial
  • Willingness to abstain from prescribed psychostimulants for 72 h prior to Visits 2 and 3 (Day -1) and 24 h following IMP administration Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Lifetime diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar I disorder, delusional disorder, autism spectrum disorder, or antisocial personality disorder as confirmed by the MINI
  • Any other psychiatric disorder that is not currently stable in symptoms and treatment
  • Any substance use disorder within 3 months prior to randomisation (excluding mild alcohol, cannabis, tobacco, and caffeine use disorders); or moderate to severe substance use disorder within the 6 months prior to randomisation (excluding tobacco and caffeine)
  • Positive drug screen. Participants with positive cannabis drug tests can be included if they do not meet criteria for moderate or severe cannabis use disorder and the investigator determines that use will not be an impediment to trial participation or accurate data collection
  • Concomitant use of psychotropic medication except for the ones below. All other psychotropic medications must be washed out at least 30 days or 5 Half-life time (t1/2) (whichever is longer) before the start of Visit 2 (Day -1)

    1. A single SSRI (selective serotonin re-uptake inhibitor) or SNRI (selective serotonin and norepinephrine re-uptake inhibitor) antidepressant that has been stable in dose and frequency for >3 months prior to randomisation
    2. A single second-generation antipsychotic at a low dose that has been stable in dose and frequency for >3 months prior to randomisation (low dose = 1 thorazine dose equivalent or less, which translates to ≤2 mg/day for risperidone, 5 mg/day for olanzapine, 75 mg/day for quetiapine, 60 mg/day for ziprasidone, and 7.5 mg/day for aripiprazole)
    3. A single sleep medication given as a nightly scheduled medication (not pro re nata) stable in agent and dose for >3 months prior to screening. Allowed sleep medications include: non-benzodiazepine Z sleep medications, antihistamines, melatonin, trazodone, and doxepin
    4. Participants taking psychostimulant medication prescribed as per label for ADHD must stop medication 72 h prior to Visits 2 and 3 (Day -1) and may resume 24 h after receiving the medication dose on the test day (i.e. 5 days total off of prescribed psychostimulant for Visit 2 and 5 days off of prescribed psychostimulant for Visit 3)
  • Any documented active or suspected or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix
  • A positive result for any active hepatitis
  • Previous randomisation in this trial Further exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Sequence 1: BI 3031185 then placebo

    Drug: BI 3031185 · Drug: Placebo

  • Experimental
    Sequence 2: Placebo then BI 3031185

    Drug: BI 3031185 · Drug: Placebo

Interventions

  • BI 3031185

  • DrugPlacebo

    Placebo matching BI 3031185

06

What researchers measure

Primary outcomes

  1. Number of participants with borderline personality disorder (BPD) reporting adverse events (AEs) deemed by the investigator to be related to the investigational medicinal product (IMP) from IMP administration to End of Study (EoS)

    Time frame: Up to 28 days

  2. Number of participants with attention deficit/hyperactivity disorder (ADHD) reporting AEs deemed by the investigator to be related to the IMP from IMP administration to EoS

    Time frame: Up to 28 days

Secondary outcomes

  1. Number of participants with BPD reporting any AEs from IMP administration to EoS

    Time frame: Up to 28 days

  2. Number of participants with ADHD reporting any AEs from IMP administration to EoS

    Time frame: Up to 28 days

07

Study locations

7 sites
  • Charité Research Organisation GmbH
    Berlin, 10117, Germany
  • Universitätsklinikum Bonn AöR
    Bonn, 53127, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt am Main, 60590, Germany
  • Martin-Luther-Universität Halle-Wittenberg
    Halle, 06112, Germany
  • Rheinhessen-Fachklinik Mainz
    Mainz, 55122, Germany
  • Zentralinstitut für seelische Gesundheit
    Mannheim, 68159, Germany
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Aug 2026, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Jun 3, 2025
StartActual
Aug 12, 2025
Primary completionActual
Aug 6, 2026
CompletionActual
Aug 6, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07001475
Responsible party
Sponsor
First posted
Jun 3, 2025
Start date
Aug 12, 2025
Primary completion
Aug 6, 2026
Completion
Aug 6, 2026
Last update
Aug 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI 3031185

Start the discussion